Abbott Rapid Dx
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Dengue - Sample Collection Study Pakistan
Role: lead
Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere
Role: lead
Lay User Evaluation of the Panbio™ HCV Self Test in an EU Population
Role: lead
Lay User Evaluation of the Panbio™ HCV Self-Test
Role: lead
Evaluation of the Diagnostic Sensitivity and Specificity of the Determine™ Syphilis Advanced Test.
Role: lead
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
Role: lead
Clinical Evaluation of the ID NOW™ CT/NG Test
Role: lead
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
Role: lead
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device
Role: lead
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
Role: lead
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs
Role: lead
Performance Evaluation of Malaria Plus Rapid Diagnostic Tests (RDTs) for the Detection of Plasmodium Infections in Patients With Symptoms Suggestive of Malaria
Role: lead
All 12 trials loaded